Enhanced histone deacetylase enzyme activity in primary myelofibrosis. (Q54783682)

3 June 2018

title

Enhanced histone deacetylase enzyme activity in primary myelofibrosis. (English)

1 reference

3 June 2018

author name string

Jen Chin Wang

1

1 reference

3 June 2018

Chi Chen

2

1 reference

3 June 2018

Theresa Dumlao

3

1 reference

3 June 2018

Seema Naik

4

1 reference

3 June 2018

Thong Chang

5

1 reference

3 June 2018

Ying-Yi Xiao

6

1 reference

3 June 2018

Inna Sominsky

7

1 reference

3 June 2018

Jack Burton

8

1 reference

3 June 2018

publication date

1 December 2008

1 reference

3 June 2018

published in

Leukemia & Lymphoma

1 reference

3 June 2018

volume

49

1 reference

3 June 2018

issue

12

1 reference

3 June 2018

page(s)

2321-2327

1 reference

3 June 2018

A gain-of-function mutation of JAK2 in myeloproliferative disorders

cites work

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Reduced expression of TGF beta1RII in agnogenic myeloid metaplasia is not due to mutation or methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Crystal structure of the nucleosome core particle at 2.8 Å resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Rational development of histone deacetylase inhibitors as anticancer agents: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

HDAC6 expression is correlated with better survival in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Expression profile of histone deacetylase 1 in gastric cancer tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

The myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Histone deacetylases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Cytoplasmic IkappaBalpha increases NF-kappaB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

Treatment with valproic acid for myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190802527699

10.1080/10428190802527699

21 January 2018

Identifiers

DOI

1 reference

3 June 2018

1 reference

3 June 2018